Newron Pharmaceuticals S.p.A. (SWX:NWRN)
8.68
+0.18 (2.12%)
Oct 22, 2026, 5:30 PM CEST
Newron Pharmaceuticals Revenue
Newron Pharmaceuticals had revenue of 3.19M EUR in the half year ending June 30, 2026, a decrease of -6.40%. This brings the company's total for the last twelve months to 10.42M, down -82.60% year-over-year. In the year 2025, Newron Pharmaceuticals had annual revenue of 19.13M, down -62.78%. That makes Newron Pharmaceuticals the 36,628th largest company in the world by revenue and 194th in Switzerland.
Revenue (ttm)
10.42M EUR
Revenue Growth
-82.60%
P/S Ratio
19.17
Revenue / Employee
385.81K EUR
Employees
27
Market Cap
184.35M CHF
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 19.13M | -32.26M | -62.78% |
| Dec 31, 2024 | 51.39M | 42.33M | 467.41% |
| Dec 31, 2023 | 9.06M | 2.96M | 48.62% |
| Dec 31, 2022 | 6.09M | 332.00K | 5.76% |
| Dec 31, 2021 | 5.76M | 504.00K | 9.59% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Bachem Holding AG | 708.53M |
| Basilea Pharmaceutica AG | 247.42M |
| Idorsia | 199.71M |
| Santhera Pharmaceuticals Holding AG | 101.50M |
| BioVersys AG | 4.62M |
| MindMaze Therapeutics Holding | 1.20M |
| Molecular Partners AG | 681.00K |
| Xlife Sciences AG | 397.23K |
Newron Pharmaceuticals News
- 14 days ago - Newron Pharmaceuticals Transcript: Investor update - Transcripts
- 14 days ago - Newron Pharmaceuticals Press release: Investor update - Filings
- 14 days ago - US FDA cites 4 deaths in Newron's schizophrenia drug trial hold - Reuters
- 14 days ago - Newron Advances Global Enrollment Despite U.S. Clinical Hold - Nasdaq
- 14 days ago - FDA Hold Review Continues As Newron Advances Phase 3 Evenamide Program - Nasdaq
- 25 days ago - FDA Maintains U.S. Enrollment Hold On Newron's Phase 3 ENIGMA-TRS 2 Schizophrenia Study - Nasdaq
- 4 weeks ago - Newron Pharmaceuticals Earnings release: H1 2026 - Filings
- 4 weeks ago - Newron Pharmaceuticals Quarterly report: H1 2026 - Filings